Status: Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).
Participants needed: 260
Trial details
Phase: Phase 3Age: 2-55Biological sex: AllType: InterventionalSponsor: EpygenixUpdated: Jul 2, 2026Locations: 26
Eligibility criteria
Males or females, ages ≥2 to ≤55 years, at the time of Screening. [+5]
Known sensitivity, allergy, or previous exposure to clemizole HCl. [+6]